BRPI0906809A2 - Compostos tricíclicos como moduladores da síntese do tnf-(alfa) e como inibidores da pde4. - Google Patents

Compostos tricíclicos como moduladores da síntese do tnf-(alfa) e como inibidores da pde4.

Info

Publication number: BRPI0906809A2
Authority: BR; Brazil
Prior art keywords: pde4; tnf; modulators; inhibitors; alpha
Prior art date: 2008-01-25

Application number

BRPI0906809-0A

Other languages

English (en)

Inventor

Adnan M M Mjalli

Bapu Gaddam

Dharma Rao Polisetti

Matthew Kostura

Mustafa Guzel

Original Assignee

High Point Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-25

Filing date

2009-01-23

Publication date

2015-07-14

2009-01-23 Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc

2015-07-14 Publication of BRPI0906809A2 publication Critical patent/BRPI0906809A2/pt

Links

101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Virology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)

BRPI0906809-0A 2008-01-25 2009-01-23 Compostos tricíclicos como moduladores da síntese do tnf-(alfa) e como inibidores da pde4. BRPI0906809A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2361708P	2008-01-25	2008-01-25
PCT/US2009/031819 WO2009094528A1 (en)	2008-01-25	2009-01-23	TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS

Publications (1)

Publication Number	Publication Date
BRPI0906809A2 true BRPI0906809A2 (pt)	2015-07-14

Family

ID=40901439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0906809-0A BRPI0906809A2 (pt)	2008-01-25	2009-01-23	Compostos tricíclicos como moduladores da síntese do tnf-(alfa) e como inibidores da pde4.

Country Status (16)

Country	Link
US (10)	US7964608B2 (pt)
EP (1)	EP2244574B1 (pt)
JP (1)	JP5406215B2 (pt)
KR (1)	KR101709141B1 (pt)
CN (1)	CN101925301B (pt)
AU (1)	AU2009206368B2 (pt)
BR (1)	BRPI0906809A2 (pt)
CA (1)	CA2711576C (pt)
EA (1)	EA018462B1 (pt)
ES (1)	ES2523169T3 (pt)
IL (1)	IL206854A (pt)
MA (1)	MA32035B1 (pt)
MX (1)	MX2010007768A (pt)
NZ (1)	NZ586695A (pt)
WO (1)	WO2009094528A1 (pt)
ZA (1)	ZA201004818B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7964608B2 (en)	2008-01-25	2011-06-21	High Point Pharmaceuticals, Llc	Tricyclic compounds as modulators of TNF-α synthesis
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR090100A1 (es) *	2012-02-21	2014-10-22	Celgene Corp	Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9611267B2 (en)	2012-06-13	2017-04-04	Incyte Holdings Corporation	Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
DK2950649T3 (da)	2013-02-01	2020-05-04	Wellstat Therapeutics Corp	Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet
TWI649318B (zh)	2013-04-19	2019-02-01	英塞特控股公司	作為ｆｇｆｒ抑制劑之雙環雜環
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en)	2015-02-20	2020-07-09	Incyte Holdings Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
BR112017026191B1 (pt) *	2015-06-17	2023-10-10	Pfizer Inc	Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos
WO2017089347A1 (en)	2015-11-25	2017-06-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201946630A (zh)	2018-05-04	2019-12-16	美商英塞特公司	Fgfr抑制劑之鹽
ES2991427T3 (es)	2018-05-04	2024-12-03	Incyte Corp	Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
CN109705037A (zh) *	2019-01-24	2019-05-03	广西师范大学	4-氨基喹啉-3-甲酸酯衍生物及其制备方法和应用
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
KR102766496B1 (ko)	2019-08-09	2025-02-10	주식회사 엘지에너지솔루션	연쇄발화 방지를 위한 에너지 드레인 저항체를 구비한 배터리 팩
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en)	2019-10-14	2024-04-25	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en)	2019-12-04	2022-06-02	Incyte Corporation	Derivatives of an FGFR inhibitor
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN111808098B (zh) *	2020-06-29	2021-08-24	Vtv治疗有限责任公司	喹啉衍生物，其药学上可接受的盐及其使用方法
AU2021315488A1 (en) *	2020-07-28	2023-03-23	Vtv Therapeutics Llc	Crystalline form of hydrochloride salt of quinoline derivative
CN116529247A (zh) *	2020-07-28	2023-08-01	维特卫治疗有限责任公司	喹啉衍生物的盐酸盐的晶型
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN116262750A (zh) *	2021-12-15	2023-06-16	上海翊石医药科技有限公司	一种芳杂环类化合物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO162019C (no)	1983-11-23	1989-10-25	Fujisawa Pharmaceutical Co	Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidoiskinolinderivater.
US4927820A (en)	1988-11-25	1990-05-22	Hoechst Roussel Pharmaceuticals Inc.	Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine
JPH0741479A (ja) *	1993-07-28	1995-02-10	Taisho Pharmaceut Co Ltd	７−アザプテリジン類およびその製造方法
WO1997044322A1 (en) *	1996-05-20	1997-11-27	Darwin Discovery Limited	Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US6930101B1 (en) *	1999-05-17	2005-08-16	The Regents Of The University Of California	Thiazolopyrimidines useful as TNFα inhibitors
US20030207845A1 (en)	2001-02-08	2003-11-06	Keating Elizabeth T.	Method and compositions for treating an inflammatory disease
NZ532278A (en)	2001-09-19	2006-02-24	Altana Pharma Ag	Combination of a PDE inhibitor and an NSAID
TW200306192A (en)	2002-01-18	2003-11-16	Bristol Myers Squibb Co	Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
PL193012B1 (pl) *	2003-06-09	2007-01-31	Univ Medyczny	3-podstawiony 1,2,3,4-tetrahydropirymido[5,4-c]cynnolin-2,4-dion i 3-podstawiony 1,2,3,4-tetrahydropirymido[5,4-c]chinolin-2,4-dion oraz sposób otrzymywania 3-podstawionego 1,2,3,4-tetrahydropirymido[5,4-c]cynnolin-2,4-dionu i 3-podstawionego 1,2,3,4-tetrahydropirymido[5,4-c]chinolin-2,4-dionu
TW200726767A (en) *	2005-07-04	2007-07-16	Astrazeneca Ab	Chemical compounds 2
US7964608B2 (en) *	2008-01-25	2011-06-21	High Point Pharmaceuticals, Llc	Tricyclic compounds as modulators of TNF-α synthesis
JP2012519159A (ja)	2009-02-27	2012-08-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬
CA2753604A1 (en)	2009-02-27	2010-09-02	Boehringer Ingelheim International Gmbh	Drug combinations containing pde4-inhibitors and nsaids
JP2013523792A (ja)	2010-04-08	2013-06-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ
EP2555773A1 (de)	2010-04-08	2013-02-13	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten

2009
- 2009-01-23 US US12/532,861 patent/US7964608B2/en active Active
- 2009-01-23 JP JP2010544436A patent/JP5406215B2/ja active Active
- 2009-01-23 KR KR1020107017176A patent/KR101709141B1/ko active Active
- 2009-01-23 BR BRPI0906809-0A patent/BRPI0906809A2/pt not_active Application Discontinuation
- 2009-01-23 AU AU2009206368A patent/AU2009206368B2/en active Active
- 2009-01-23 ES ES09704760.9T patent/ES2523169T3/es active Active
- 2009-01-23 NZ NZ586695A patent/NZ586695A/en not_active IP Right Cessation
- 2009-01-23 EP EP09704760.9A patent/EP2244574B1/en active Active
- 2009-01-23 WO PCT/US2009/031819 patent/WO2009094528A1/en not_active Ceased
- 2009-01-23 CN CN200980102961.0A patent/CN101925301B/zh active Active
- 2009-01-23 EA EA201070884A patent/EA018462B1/ru not_active IP Right Cessation
- 2009-01-23 CA CA2711576A patent/CA2711576C/en active Active
- 2009-01-23 MX MX2010007768A patent/MX2010007768A/es active IP Right Grant
2010
- 2010-07-07 IL IL206854A patent/IL206854A/en active IP Right Grant
- 2010-07-08 ZA ZA2010/04818A patent/ZA201004818B/en unknown
- 2010-07-23 MA MA33045A patent/MA32035B1/fr unknown
2011
- 2011-03-04 US US13/040,382 patent/US8853226B2/en active Active
2012
- 2012-03-02 US US13/410,628 patent/US8329715B2/en active Active
2014
- 2014-09-04 US US14/477,302 patent/US9163022B2/en active Active
2015
- 2015-09-10 US US14/850,012 patent/US9393245B2/en active Active
2016
- 2016-06-16 US US15/184,392 patent/US9687489B2/en active Active
2017
- 2017-05-22 US US15/600,942 patent/US9833457B2/en active Active
- 2017-11-01 US US15/800,794 patent/US10085990B2/en active Active
2018
- 2018-08-27 US US16/113,327 patent/US10391097B2/en active Active
2019
- 2019-07-10 US US16/507,219 patent/US10568888B2/en active Active

Also Published As

Publication number	Publication date
WO2009094528A1 (en)	2009-07-30
JP2011510929A (ja)	2011-04-07
US10568888B2 (en)	2020-02-25
KR101709141B1 (ko)	2017-02-22
AU2009206368B2 (en)	2014-12-11
US9833457B2 (en)	2017-12-05
US20150374700A1 (en)	2015-12-31
EP2244574A1 (en)	2010-11-03
CA2711576C (en)	2016-06-21
EA201070884A1 (ru)	2011-04-29
IL206854A0 (en)	2010-12-30
US20120172381A1 (en)	2012-07-05
EP2244574B1 (en)	2014-10-01
US20190336506A1 (en)	2019-11-07
NZ586695A (en)	2011-12-22
US7964608B2 (en)	2011-06-21
ZA201004818B (en)	2011-03-30
US20100190808A1 (en)	2010-07-29
MA32035B1 (fr)	2011-01-03
IL206854A (en)	2014-04-30
ES2523169T3 (es)	2014-11-21
CA2711576A1 (en)	2009-07-30
JP5406215B2 (ja)	2014-02-05
US20140371250A1 (en)	2014-12-18
US20110160234A1 (en)	2011-06-30
US10391097B2 (en)	2019-08-27
US9687489B2 (en)	2017-06-27
EP2244574A4 (en)	2012-01-11
US20180071297A1 (en)	2018-03-15
US9393245B2 (en)	2016-07-19
US20160296526A1 (en)	2016-10-13
MX2010007768A (es)	2010-11-09
US20170252343A1 (en)	2017-09-07
US9163022B2 (en)	2015-10-20
AU2009206368A1 (en)	2009-07-30
US20180360839A1 (en)	2018-12-20
CN101925301A (zh)	2010-12-22
US8329715B2 (en)	2012-12-11
HK1147913A1 (en)	2011-08-26
EA018462B1 (ru)	2013-08-30
KR20100103661A (ko)	2010-09-27
CN101925301B (zh)	2014-09-17
US8853226B2 (en)	2014-10-07
US10085990B2 (en)	2018-10-02

Legal Events

Date	Code	Title	Description
2017-04-25	B25D	Requested change of name of applicant approved	Owner name: VTVX HOLDINGS II LLC (US)
2017-05-16	B25A	Requested transfer of rights approved	Owner name: VTV THERAPEUTICS LLC (US)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-24	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-08-13	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
BRPI0906809A2 (pt)	2015-07-14	Compostos tricíclicos como moduladores da síntese do tnf-(alfa) e como inibidores da pde4.
BRPI0808192A2 (pt)	2019-09-24	composto e composições como moduladores de atividades de gpr119
EP2326631A4 (en)	2012-03-21	MIF MODULATORS
BRPI0908851A2 (pt)	2017-05-30	compostos e composições como moduladores da atividades de gpr119
BRPI0909037A2 (pt)	2017-09-26	compostos e composições como moduladores da atividade de tlr
BRPI0915867A2 (pt)	2017-06-20	4-fenoximetilpiperidinas como moduladores de atividade de gpr119
BRPI0917017A2 (pt)	2016-02-16	inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
BRPI1012129A2 (pt)	2016-03-29	enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
MA32938B1 (fr)	2012-01-02	Composes organiques
BRPI0918449A2 (pt)	2019-09-24	compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso
AP2011005779A0 (en)	2011-08-31	Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators.
BRPI0911118A2 (pt)	2015-10-06	composto e compisições como moduladores de atividade de gpr119
HRP20180718T1 (hr)	2018-07-13	Oligopeptidni spojevi i njihova upotreba
DK3225251T3 (da)	2020-03-16	Modulering af pro-neurotrofinaktivitet
BRPI0907584A2 (pt)	2015-07-21	Composto e composições como moduladores de atividade de gpr119
DK2512451T3 (da)	2016-06-06	Modulator
EP2116533A4 (en)	2012-01-25	Glucokinase AKTIVATOR
BRPI1011784A2 (pt)	2016-03-22	compostos bicíclicos e tricíclicos como inibidores de kat ii
DK2373652T3 (da)	2014-01-20	Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
DK3144567T3 (da)	2019-11-25	Dynamisk tætning
EP2258426A4 (en)	2013-09-04	DRUGS CONTAINER
EP2467376A4 (en)	2013-01-16	BICYCLIC HETEROARYL HEMMER OF PDE4
EP2311712A4 (en)	2012-05-09	PLATE-BODY BODY
BRPI0911274A2 (pt)	2015-09-29	vedações pressurizadas internamente
EP2300612A4 (en)	2012-02-22	MODULATION OF GM98 (MRF) IN REMYLELINING